Post by Cirrus Therapeutics

Last week, CEO and Co-founder Ying Kai Chan, PhD, and Director, Pipeline and Site Head, Singapore Si Hui Tan, PhD, represented Cirrus Therapeutics at BIO International Convention 2026 in San Diego, one of the largest global convenings in biotechnology, drawing more than 20,000 industry leaders for four days of partnering, scientific exchange, and strategic discussion. For Cirrus, the week was an energizing one. Kai and Si Hui attended the Singapore Reception: Accelerating Global Biotech Innovations, reconnecting with the fast-growing Singapore life sciences community. The team also met with Wen Qi Ho, Therapeutics Lead at ClavystBio, whose continued partnership supports Cirrus' growth as a global ocular immunology company. And for Kai, the week brought a meaningful reunion with the Termeer Institute network and its growing community of biotech CEOs and industry leaders. "BIO is a powerful reminder that progress in biotech depends on more than strong science alone," said Kai. "It takes trusted partners, global connections, and a community willing to build together. I came away from the week encouraged by the quality of the conversations and optimistic about what lies ahead." As Cirrus advances gene and cell therapies for dry AMD, geographic atrophy, and other chronic blinding diseases, gatherings like BIO strengthen the partnerships, perspective, and global relationships that move meaningful science toward patients. Follow Cirrus Therapeutics for updates on our work in ocular immunology, healthy visual aging, and next-generation therapies for blinding diseases. #vision #AMD #DryAMD #WetAMD #optometry #opthalmology #healthcare #science #STEM #biotech #biopharma #research #lifesciences